China approves seaweed-based Alzheimer’s drug. It’s the first new one in 17 years
5 years, 4 months ago

China approves seaweed-based Alzheimer’s drug. It’s the first new one in 17 years

CNN  

CNN — Authorities in China have approved a drug for the treatment of Alzheimer’s disease, the first new medicine with the potential to treat the cognitive disorder in 17 years. In September, the team behind the new drug, led by Geng Meiyu at the Shanghai Institute of Materia Medica under the Chinese Academy of Sciences, said they were inspired to look into seaweed due to the relatively low incidence of Alzheimer’s among people who consume it regularly. Vincent Mok, who heads the neurology division at the Chinese University of Hong Kong, said the new drug showed “encouraging results” when compared to acetylcholinesterase inhibitors – the existing treatment for mild to severe Alzheimer’s. “It will also open up new avenues for Alzheimer’s research, focusing on the gut microbiome.” Since very little is known about the mechanisms of the new drug, Mok said it should also be probed to see if it could have a protective effect and possibly slow down the progression of the disease in patients who have yet to develop strong symptoms of dementia.

China Drug Green Valley Oligomannate  seaweedbased  17  gut  treatment  china  green  pharmaceutical  trial  oligomannate  drug  approves  alzheimers  clinical  disease

History of this topic

New Alzheimer's drug: only a few eligible for treatment
4 months, 2 weeks ago

New Alzheimer's drug: only a few eligible for treatment

NL Times  

It is estimated that less than one in ten people with dementia are eligible for treatment with Lecanemab or Leqembi, the slowing agent that is still allowed on the European market by the European Medicines Agency. That is why Alzheimer Nederland calls for a fast track "so that patients and their families are not unnecessarily in uncertainty for a long …

Eli Lilly Alzheimer's drug approved by US FDA
8 months, 4 weeks ago

Eli Lilly Alzheimer's drug approved by US FDA

Hindustan Times  

By Bhanvi Satija Eli Lilly Alzheimer's drug approved by US FDA July 2 - The U.S. Food and Drug Administration on Tuesday approved Eli Lilly's treatment for early Alzheimer's, making it the second therapy for slowing progression of the brain-wasting disease that will be available to U.S. patients. The approval for donanemab, to be sold under brand name Kisunla, followed …

FDA approves another Alzheimer's drug that can slow disease in its early stages
8 months, 4 weeks ago

FDA approves another Alzheimer's drug that can slow disease in its early stages

Hindustan Times  

U.S. officials have approved another Alzheimer’s drug that can modestly slow the disease, providing a new option for patients in the early stages of the incurable, memory-destroying ailment. “It’s been difficult as a dementia specialist — I diagnose my patients with Alzheimer’s and then every year I see them get worse and they progress until they die.” Both Kisunla and …

FDA approves a second Alzheimer's drug that can modestly slow disease
8 months, 4 weeks ago

FDA approves a second Alzheimer's drug that can modestly slow disease

The Independent  

For free real time breaking news alerts sent straight to your inbox sign up to our breaking news emails Sign up to our free breaking news emails Sign up to our free breaking news emails SIGN UP I would like to be emailed about offers, events and updates from The Independent. Read our privacy policy U.S. officials have approved another …

FDA approves a second Alzheimer’s drug that can modestly slow disease
8 months, 4 weeks ago

FDA approves a second Alzheimer’s drug that can modestly slow disease

Associated Press  

WASHINGTON — U.S. officials have approved another Alzheimer’s drug that can modestly slow the disease, providing a new option for patients in the early stages of the incurable, memory-destroying ailment. It’s only the second drug that’s been convincingly shown to delay cognitive decline in patients, following last year’s approval of a similar drug from Japanese drugmaker Eisai. “It’s been difficult …

FDA approves a second Alzheimer's drug that can modestly slow disease
8 months, 4 weeks ago

FDA approves a second Alzheimer's drug that can modestly slow disease

NPR  

FDA approves a second Alzheimer's drug that can modestly slow disease toggle caption Eli Lilly and Company/AP WASHINGTON — U.S. officials have approved another Alzheimer’s drug that can modestly slow the disease, providing a new option for patients in the early stages of the incurable, memory-destroying ailment. It’s only the second drug that’s been convincingly shown to delay cognitive decline …

It’s the first drug shown to slow Alzheimer’s. Why is it off to a slow start?
11 months, 2 weeks ago

It’s the first drug shown to slow Alzheimer’s. Why is it off to a slow start?

Associated Press  

The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage. “As we learn more, we’ll expand and extend it.” The Mayo Clinic in Rochester, Minnesota, started using Leqembi in October but only for patients …

FDA will take a deeper look into the safety and effectiveness of Lilly experimental Alzheimer’s drug
1 year ago

FDA will take a deeper look into the safety and effectiveness of Lilly experimental Alzheimer’s drug

Associated Press  

INDIANAPOLIS — Federal regulators put off a decision on whether to approve an Eli Lilly Alzheimer’s drug by making an unusual request to have outside advisers look at the treatment. Eli Lilly and Co. Executive Vice President Anne White said in a statement that the Indianapolis-based company remains confident in donanemab’s potential and will work with the FDA. Donanemab is …

Biogen will stop selling its controversial Alzheimer’s drug Aduhelm
1 year, 2 months ago

Biogen will stop selling its controversial Alzheimer’s drug Aduhelm

Associated Press  

Biogen will stop selling its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a few years ago. The company also is helping Japanese drugmaker Eisai sell another Alzheimer’s treatment, Leqembi, which received full FDA approval last summer. When Aduhelm debuted in 2021, it was the first new Alzheimer’s drug in nearly two …

A trial to test a new path for preventing Alzheimer’s
1 year, 7 months ago

A trial to test a new path for preventing Alzheimer’s

The Hindu  

Last month, a wave of excitement swept through the world of Alzheimer’s research after Eli Lilly published results of a trial of their drug, donanemab. Elevated levels of amyloid form plaque and trigger another protein called tau that damages brain cells, causing the cognitive decline typified by the disease. One of these is the oxidative stress hypothesis, which suggests that …

Second Alzheimer’s drug in pipeline can slow the disease by a few months but with safety risk
1 year, 8 months ago

Second Alzheimer’s drug in pipeline can slow the disease by a few months but with safety risk

LA Times  

New research shows an experimental Alzheimer’s drug from Eli Lilly and Co. can modestly slow patients’ inevitable worsening, though it comes with safety concerns. Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported this week. “Diabetes doesn’t have a cure either — it doesn’t mean you can’t have very meaningful …

‘Turning point’ in the fight against Alzheimer’s as drug found to slow disease
1 year, 8 months ago

‘Turning point’ in the fight against Alzheimer’s as drug found to slow disease

The Independent  

Sign up for our free Health Check email to receive exclusive analysis on the week in health Get our free Health Check email Get our free Health Check email SIGN UP I would like to be emailed about offers, events and updates from The Independent. Risk can increase with age, impacting one in 14 people over the age of 65 …

New Alzheimer’s wonder drug ‘can slow disease progression by 60pc’
1 year, 8 months ago

New Alzheimer’s wonder drug ‘can slow disease progression by 60pc’

The Telegraph  

The NHS has just 88 positron emission tomography scanners which can detect amyloid plaques in the brain, one of the lowest per capita in the developed world. Hilary Evans, the chief executive of Alzheimer’s Research UK said: “Probably only two per cent of the people who could benefit from these drugs would necessarily get them because of those hurdles in …

An experimental Alzheimer's drug outperforms one just approved by the FDA
1 year, 8 months ago

An experimental Alzheimer's drug outperforms one just approved by the FDA

NPR  

An experimental Alzheimer's drug outperforms one just approved by the FDA Enlarge this image toggle caption Eli Lilly and Company Eli Lilly and Company Patients in the early stages of Alzheimer's may soon have a new option to stave off the loss of memory and thinking. "This is the biggest effect that's ever been seen in an Alzheimer's trial for …

New drug for Alzheimer's gives hope and ushers in new era in fighting the disease, says doctor
1 year, 8 months ago

New drug for Alzheimer's gives hope and ushers in new era in fighting the disease, says doctor

NL Times  

Alzheimer's used to be a disease that could not be cured. On Monday, however, the results of the second new drug for Alzheimer's will be announced, and that seems to herald a new era, says neurologist Niels Prins, director of the Brain Research Center. "It will be possible to counteract the disease, and that has never been done before in …

First drug to slow Alzheimer's progression approved in US | 5 points
1 year, 8 months ago

First drug to slow Alzheimer's progression approved in US | 5 points

Hindustan Times  

US drug regulator on Thursday granted full approval to Alzheimer's drug Leqembi, manufactured by a Japanese firm Eisai. The company had earlier received conditional approval from the Food and Drug Administration in January based on early results suggesting Leqembi worked on Alzheimer's patients by clearing a sticky brain plaque linked to the disease. The drug is among the most potent …

Alzheimer: This Country Has Approved New Drug That Will Combat Cognitive Decline
1 year, 8 months ago

Alzheimer: This Country Has Approved New Drug That Will Combat Cognitive Decline

News 18  

The US drug regulator gave full approval to a new Alzheimer’s medicine on Thursday, a move that makes it more widely available to the public through government-run health insurance for the elderly. “This confirmatory study verified that it is a safe and effective treatment for patients with Alzheimer’s disease,” senior FDA official Teresa Buracchio said in a statement. “This treatment, …

Alzheimer’s drug gets FDA panel’s backing, setting the stage for broader use
1 year, 9 months ago

Alzheimer’s drug gets FDA panel’s backing, setting the stage for broader use

Associated Press  

WASHINGTON — Health advisers on Friday unanimously backed the full approval of a closely watched Alzheimer’s drug, a key step toward opening insurance coverage to U.S. seniors with early stages of the brain-robbing disease. The FDA panel of outside advisers voted 6-0 that a large company study confirmed the drug’s benefits for patients with mild or early Alzheimer’s. The FDA’s …

World ‘on cusp of first generation of treatments for Alzheimer’s’ as new drug ‘slows symptoms’
1 year, 10 months ago

World ‘on cusp of first generation of treatments for Alzheimer’s’ as new drug ‘slows symptoms’

The Independent  

The world is “on the cusp of a first generation of treatments for Alzheimer’s disease”, experts have said, as a new drug was found to slow cognitive and functional decline. Daniel Skovronsky, Eli Lilly’s chief scientific and medical officer, said: “This is the first phase 3 trial of any investigational medicine for Alzheimer’s disease to deliver 35% slowing of clinical …

New Alzheimer's drug appears to slow cognitive decline by 35 per cent, according to Eli Lilly
1 year, 10 months ago

New Alzheimer's drug appears to slow cognitive decline by 35 per cent, according to Eli Lilly

ABC  

An experimental Alzheimer's drug appeared to slow progression of the mind-robbing disease in a large new study and experts are optimistic but warning of risks. Key points: The drug is the strongest evidence yet that removing sticky amyloid plaques from the brain is beneficial for patients The new drug, donanemab, met all goals of the trial An expert warns there …

EXPLAINER: New drug slows Alzheimer’s but comes with caveats
2 years, 2 months ago

EXPLAINER: New drug slows Alzheimer’s but comes with caveats

Associated Press  

WASHINGTON — A new Alzheimer’s drug is hitting the market — the first with clear-cut evidence that it can slow, by several months, the mind-robbing disease. In Eisai’s 18-month study of nearly 1,800 people, Leqembi appeared to delay early-stage patients from getting worse by about five months. People who got the drug still worsened but not as rapidly as those …

US approves Alzheimer’s drug that modestly slows disease
2 years, 2 months ago

US approves Alzheimer’s drug that modestly slows disease

Associated Press  

WASHINGTON — U.S. health officials on Friday approved a closely watched Alzheimer’s drug that’s been shown to modestly slow the early stages of the brain-robbing disease, albeit with potential safety risks that doctors and patients will have to carefully weigh. Last week, a congressional report found that FDA’s approval of a similar Alzheimer’s drug called Aduhelm — also from Biogen …

U.S. approves Alzheimer’s drug that modestly slows disease
2 years, 2 months ago

U.S. approves Alzheimer’s drug that modestly slows disease

LA Times  

This Dec. 21, 2022 image provided by Eisai in January 2023, shows vials and packaging for their medication Leqembi. U.S. health officials on Friday approved a closely watched Alzheimer’s drug that modestly slows the brain-robbing disease, albeit with potential safety risks that patients and their doctors will have to carefully weigh. Last week, a congressional report found that FDA’s approval …

FDA approves Alzheimer's drug that appears to modestly slow disease
2 years, 2 months ago

FDA approves Alzheimer's drug that appears to modestly slow disease

NPR  

FDA approves Alzheimer's drug that appears to modestly slow disease Enlarge this image toggle caption David Duprey/AP David Duprey/AP The Food and Drug Administration has approved a drug that may help people in the early stages of Alzheimer's maintain their mental abilities. "This is a milestone for people eligible for this treatment, for their families, for the research community," says …

Alzheimer's drug breakthrough 阿尔茨海默病治疗药物获重大突破
2 years, 3 months ago

Alzheimer's drug breakthrough 阿尔茨海默病治疗药物获重大突破

China Daily  

媒体英语 Alzheimer's drug breakthrough 阿尔茨海默病治疗药物获重大突破 Play audio file 新试验发现首个减缓阿尔茨海默病对患者大脑损伤的药物，这个名为 “ lecanemab ” 的药物 “意义重大”。这项试验的结果为此领域几十年的高失败率画上句号，并表明用药物治疗阿尔茨海默病（最常见的失智症）的新时代并非遥不可及。 News of the first drug that can slow the progression of Alzheimer's has been called historic and prompted huge excitement among researchers and charities. It is only suitable for those with early-stage Alzheimer's, but few patients in the UK have the confirmatory diagnostic test needed to …

Explained | Will new drug slow progress of Alzheimer’s?
2 years, 3 months ago

Explained | Will new drug slow progress of Alzheimer’s?

The Hindu  

The story so far: In late November, news of the success of a drug to reduce cognitive decline in patients with Alzheimer’s disease burst on the horizon with all the promise of being a silver bullet. This class of drugs does precisely that.” As per the NEJM paper, the clinical trial, conducted over 18-months, a multi-centre, double-blind, phase 3 trial, …

Breakthrough: A drug slows Alzheimer’s by 5 months, but will it make a big difference?
2 years, 4 months ago

Breakthrough: A drug slows Alzheimer’s by 5 months, but will it make a big difference?

Firstpost  

On Tuesday, Japanese drugmaker Eisai and its US partner Biogen reported that an experimental Alzheimer’s drug had modestly slowed the brain disease’s inevitable worsening. However, it is unclear how much of a difference this would make in people’s lives An experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening, researchers reported Tuesday — but it remains unclear how much …

New Alzheimer’s drug hailed as ‘beginning of the end’ in search for treatment
2 years, 4 months ago

New Alzheimer’s drug hailed as ‘beginning of the end’ in search for treatment

The Independent  

Get the free Morning Headlines email for news from our reporters across the world Sign up to our free Morning Headlines email Sign up to our free Morning Headlines email SIGN UP I would like to be emailed about offers, events and updates from The Independent. Read our privacy policy Experts have hailed the “beginning of the end” in the …

New drug appears to slow Alzheimer’s, but can it make a real difference?
2 years, 4 months ago

New drug appears to slow Alzheimer’s, but can it make a real difference?

LA Times  

An experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening, researchers reported Tuesday — but it remains unclear how much difference that might make in people’s lives. Japanese drugmaker Eisai and its U.S. partner, Biogen, had announced earlier this fall that the drug, lecanemab, appeared to work, a badly needed bright spot after repeated disappointments in the quest for …

Alzheimer’s drug shows promise in early results of study
2 years, 6 months ago

Alzheimer’s drug shows promise in early results of study

Associated Press  

Shares of Biogen and other drugmakers researching Alzheimer’s disease soared Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease in a late-stage study. The drugmaker said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo or fake drug after 18 months of the infused treatment. …

New approach to prevent dementia: Study
2 years, 7 months ago

New approach to prevent dementia: Study

Hindustan Times  

Researchers have discovered a new druggable mechanism that could help prevent dementia. New approach to prevent dementia: Study Amyloid beta accumulation in the brain is the first step in the development of Alzheimer's dementia. In this study, published Aug. 24 in the journal Brain, researchers found a way to increase the clearance of waste products from the brains of mice …

Ad campaign for controversial Alzheimer’s drug will ‘overly medicalize’ normal age-related memory loss, some experts say
3 years, 8 months ago

Ad campaign for controversial Alzheimer’s drug will ‘overly medicalize’ normal age-related memory loss, some experts say

CNN  

CNN — Do you sometimes lose your train of thought or feel a bit more anxious than is typical for you? The campaign — which also includes a detailed “It’s particularly egregious because they are trying to convince people with either normal memories or normal age-related decline that they are ill and they need a drug,” said Dr. Adriane Fugh-Berman, …

Does new Alzheimer’s drug actually work? It may take until 2030 or later to find out
3 years, 8 months ago

Does new Alzheimer’s drug actually work? It may take until 2030 or later to find out

LA Times  

Charles Flagg, who has Alzheimer’s disease, receives an IV as part of the clinical trial for the controversial drug Aduhelm. When a controversial Alzheimer’s drug won U.S. approval, surprise over the decision quickly turned to shock at how long it might take to find out if it really works — nine years. “We think nine years is unacceptable and our …

Alzheimer’s drug stirs hope for patients, worry for doctors
3 years, 9 months ago

Alzheimer’s drug stirs hope for patients, worry for doctors

LA Times  

Michele Hall, who has early Alzheimer’s, calls the new drug Aduhelm “the first tiny glimmer of hope” that she might have more quality time with her husband and their three adult children. In the weeks since a new Alzheimer’s drug was approved, hopeful patients have bombarded Dr. Alireza Atri with calls and emails about a treatment that has sparked both …

Alzheimer’s drug stirs hope for patients, worry for doctors
3 years, 9 months ago

Alzheimer’s drug stirs hope for patients, worry for doctors

Associated Press  

In the weeks since a new Alzheimer’s drug was approved, hopeful patients have bombarded Dr. Alireza Atri with calls and emails about a treatment that has sparked both excitement and skepticism. “I don’t want to see people pull their mothers from nursing homes to get this treatment,” said Dr. Babak Tousi, a Cleveland Clinic geriatrician who consulted with Biogen and …

US Approves First New Alzheimer's Drug in Almost Two Decades
3 years, 9 months ago

US Approves First New Alzheimer's Drug in Almost Two Decades

News 18  

The United States on Monday approved a drug called Aduhelm to treat patients with Alzheimer’s, the first new medicine against the disease in almost two decades and the first to address cognitive decline linked to the condition. The decision was highly anticipated but also contentious, because an independent expert panel convened by the regulatory Food and Drug Administration last November …

FDA Approves Much-Debated Alzheimer’s Drug Panned By Experts
3 years, 9 months ago

FDA Approves Much-Debated Alzheimer’s Drug Panned By Experts

Huff Post  

LOADING ERROR LOADING WASHINGTON — Government health officials on Monday approved the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn’t been shown to help slow the brain-destroying disease. The Food and Drug Administration said it granted approval to the drug developed by Biogen for patients with Alzheimer’s disease. …

FDA approves much-debated Alzheimer’s drug panned by experts
3 years, 9 months ago

FDA approves much-debated Alzheimer’s drug panned by experts

LA Times  

A researcher works on the development of the Alzheimer’s drug aducanumab at Biogen in Cambridge, Mass. “We are extremely aware of the gradual and cumulative devastation that Alzheimer’s disease causes,” Dr. Patrizia Cavazzoni, director of the FDA Center for Drug Evaluation and Research, explained in a statement. Dr. Marsel Mesulam, director of the Cognitive Neurology and Alzheimer’s Disease Center at …

China Alzheimer drug seeks global legitimacy with U.S. trial
4 years, 4 months ago

China Alzheimer drug seeks global legitimacy with U.S. trial

Hindustan Times  

A new Chinese therapy for Alzheimer’s is embarking on a much-anticipated U.S. study -- the latest bid to revive hopes in the multibillion-dollar search for an effective medicine against the incurable disease. Shanghai Green Valley Pharmaceutical Co. said this week that researchers have identified the first patient from a screening process for the U.S. arm of the 4 billion yuan …

Alzheimer’s disease drug could get closer to FDA approval
4 years, 4 months ago

Alzheimer’s disease drug could get closer to FDA approval

CNN  

CNN — The US Food and Drug Administration soon will consider whether to approve a new Alzheimer’s drug for the first time in almost two decades. The agency’s Peripheral and Central Nervous System Drugs Advisory Committee will meet on Friday to discuss aducanumab, an experimental treatment administered through intravenous infusion for early Alzheimer’s disease. “There has not been an approval …

我国原创治疗阿尔茨海默病新药获批上市
5 years, 4 months ago

我国原创治疗阿尔茨海默病新药获批上市

China Daily  

11月2日，国家药品监督管理局批准了上海绿谷制药有限公司治疗阿尔茨海默病新药——九期一（○内加“R”）（甘露特钠，代号：GV—971）的上市申请。 甘露特钠，代号：GV—971 A homegrown drug, GV-971,which is the world's first innovative therapy for treating Alzheimer's disease in 17 years will be available to Chinese patients before the end of this year, its developers said on Sunday. 11月3日，治疗阿尔茨海默病国产新药——九期一（○内加“R”）（甘露特钠，代号：GV—971）的研发机构表示，该药将在今年年底与国内患者见面，填补了全球阿尔茨海默病治疗领域17年无新药上市的空白。 该药以海洋褐藻提取物为原料（materials extracted from brown algae），制备获得的低分子酸性寡糖化合物，可明显改善轻度至中度阿尔茨海默病患者认知功能（treat mild to moderate forms of the disease and improve cognition）。 Alzheimer's disease, an irreversible and progressive brain disorder …

Biogen reanalyzes studies, presses ahead on Alzheimer’s drug
5 years, 5 months ago

Biogen reanalyzes studies, presses ahead on Alzheimer’s drug

Associated Press  

Biogen Inc. said Tuesday it will seek federal approval for a medicine to treat early Alzheimer’s disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia. The two studies tested aducanumab, given as monthly infusions, in more than 3,000 patients with mild cognitive impairment or early dementia due to Alzheimer’s. …

Doctors warn false Alzheimer's cure
6 years, 1 month ago

Doctors warn false Alzheimer's cure

Deccan Chronicle  

Hyderabad: Tablets, capsules and oils which are being marketed on social media and websites to treat or cure Alzheimer’s disease are fraudulent and not scientifically proven, stated the Food and Drug Administration in a warning issued to the companies marketing these products. Dr Chandrashekar Naidu, senior neurologist at KIMS Hospital explained, “There is only symptomatic treatment for Alzheimer’s where according …

ANOTHER Alzheimer's drug fails: Trials of an experimental treatment cancelled two years early
6 years, 2 months ago

ANOTHER Alzheimer's drug fails: Trials of an experimental treatment cancelled two years early

Daily Mail  

Roche Holding will halt two late-stage clinical trials of its crenezumab drug for early Alzheimer's disease after an interim analysis indicated it was unlikely to hit its primary goal, the Swiss drugmaker said on Wednesday. Roche said an Alzheimer's Prevention Initiative study of crenezumab in familial Alzheimer's disease in Colombia would continue and that it remained committed to ongoing clinical …

Why it’s so hard to treat dementia
7 years, 2 months ago

Why it’s so hard to treat dementia

CNN  

Story highlights Dementia is not a single disease but a complex problem with more than 50 underlying causes Most drug treatments in development target pathology of Alzheimer's, the most common form of dementia Finding a cure for neurodegenerative diseases such as Alzheimer’s is challenging. Last week, pharmaceutical giant Pfizer announced it will stop research into developing drugs to treat Alzheimer’s …

Alzheimer’s drug is doable by 2025, experts believe
8 years, 3 months ago

Alzheimer’s drug is doable by 2025, experts believe

CNN  

Story highlights The biology underlying Alzheimer's disease is still not fully understood Two key theories are the basis for drugs in development today CNN — The results of recent trials that tested much-anticipated Alzheimer’s disease drugs dashed the hopes of patients with the debilitating condition. “It’s our most developed program in Alzheimer’s disease,” said Samantha Budd Haeberlein, vice president of …

Eli Lilly’s promising Alzheimer’s drug fails in clinical trial
8 years, 4 months ago

Eli Lilly’s promising Alzheimer’s drug fails in clinical trial

CNN  

Story highlights 2,100 patients participated in the multi-national study Patients taking the drug didn't experience significantly different results from those taking a placebo CNN — A large trial of a drug to treat dementia caused by Alzheimer’s disease has ended in failure after people receiving the treatment showed no significant improvements to those taking a placebo. While two well-established risk …

Is new Alzheimer’s drug a ‘game-changer?’
8 years, 7 months ago

Is new Alzheimer’s drug a ‘game-changer?’

CNN  

Story highlights An experimental drug cleared plaque from the brains of early stage Alzheimer's patients But cognitive benefits of the Biogen drug have not been proved CNN — An experimental drug shattered and removed toxic plaques in the brains of patients with early-stage Alzheimer’s disease, researchers said Thursday. Given to patients once a month for a year, infusions of the …

Is new Alzheimer’s drug a ‘game-changer?’
8 years, 7 months ago

Is new Alzheimer’s drug a ‘game-changer?’

CNN  

Story highlights An experimental drug cleared plaque from the brains of early stage Alzheimer's patients But cognitive benefits of the Biogen drug have not been proved CNN — An experimental drug shattered and removed toxic plaques in the brains of patients with early-stage Alzheimer’s disease, researchers said Thursday. Given to patients once a month for a year, infusions of the …

Discover Related